威尔药业(603351) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥312,206,558.92, representing a year-on-year increase of 2.13%[2] - Net profit attributable to shareholders for Q3 2024 was ¥34,002,055.99, up 36.64% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥33,884,294.46, reflecting a 36.69% increase year-on-year[2] - Basic earnings per share for Q3 2024 were ¥0.25, an increase of 31.58% year-on-year[2] - Total operating revenue for Q3 2024 was 128,898,149.74 CNY, an increase from 83,948,045.08 CNY in Q3 2023, representing a growth of approximately 53.5%[14] - Net profit attributable to shareholders of the parent company reached 112,897,296.64 CNY, up from 78,271,460.39 CNY in the same period last year, reflecting a growth of about 44.4%[15] - The total profit for Q3 2024 was 128,731,004.47 CNY, compared to 83,796,714.03 CNY in Q3 2023, representing an increase of approximately 53.5%[14] Cash Flow - The net cash flow from operating activities for Q3 2024 was ¥84,285,195.63, a significant increase of 89.19% compared to the same period last year[2] - The company experienced a significant increase in cash flow due to higher operating revenue, contributing to a year-to-date cash flow increase of 190.11%[5] - Cash flow from operating activities for the first three quarters of 2024 was 161,205,186.32 CNY, significantly higher than 55,567,467.81 CNY in the same period of 2023, marking an increase of about 189%[16] - The company recorded a net cash inflow from operating activities of 842,784,174.82 CNY in the first three quarters of 2024, compared to 617,267,798.70 CNY in the same period of 2023, indicating a growth of about 36.5%[16] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,279,437,409.53, a slight increase of 0.02% from the end of the previous year[3] - Shareholders' equity attributable to the parent company increased by 5.41% year-on-year, reaching ¥1,670,212,016.14[3] - The company's total liabilities amounted to RMB 603,601,125.29, down from RMB 686,221,568.07, indicating a decrease of 12.1%[12] - Short-term borrowings decreased to RMB 331,185,736.11 from RMB 362,221,219.44, a reduction of 8.6%[12] - The retained earnings increased to RMB 528,935,171.78 from RMB 456,669,614.74, representing a growth of 15.8%[12] Research and Development - Research and development expenses for Q3 2024 were 47,691,176.39 CNY, compared to 40,564,145.19 CNY in Q3 2023, indicating an increase of approximately 17.5%[14] Investment Activities - The net cash flow from investing activities was -65,505,220.62, compared to -51,549,090.29 in the previous period, indicating an increase in cash outflow for investments[17] - Cash paid for the acquisition of fixed assets and intangible assets was 43,475,153.98, down from 53,159,960.36, indicating a reduction in capital expenditures[17] - The company reported a cash outflow of 1,400,000.00 related to other investment activities, down from 2,050,000.00, suggesting a decrease in ancillary investment costs[17] Financing Activities - Cash inflow from financing activities totaled 242,886,361.11, down from 365,339,633.34 in the previous period, reflecting a decrease in financing received[17] - Cash outflow for debt repayment was 268,300,000.00, an increase from 241,020,000.00 in the previous period, showing higher debt servicing costs[17] - The net cash flow from financing activities was -84,016,668.97, a significant decline from a positive cash flow of 68,540,370.35 in the previous period, indicating a shift in financing strategy[17] Other Information - The company has not reported any significant changes in major shareholders or their participation in margin trading[10] - There are no new product launches or technological developments mentioned in the report[10]